The World Health Organization on Wednesday issued a new standard for countries implementing rapid diagnostics to detect tuberculosis. The guidelines are the first-ever WHO has issued for rapid TB testing.

The penetration rate of blood glucose meters among diabetes patients in China is far lower than that in developed countries, and there is a huge market space for blood glucose meters.

UK circulating tumor cell firm Angle said Wednesday that it has signed an agreement with BioView to develop a liquid biopsy HER2 assay using its cell isolation technology, Parsortix, and BioView's automated microscopy systems and software.

Meridian Bioscience said Wednesday the US Food and Drug Administration has cleared the firm's Curian Shiga Toxin immunoassay, expanding the firm's gastrointestinal disease product line.

Berry Genomics recently announced that it will acquire NeoGenomics, a US-based blood testing company, for US$2.4 billion to further strengthen its oncology testing business.

Juntendo University, Sysmex, and ThinkCyte said Tuesday that they are collaborating on research into the early detection and treatment of chronic myelogenous leukemia (CML).

OpGen announced on Tuesday that it has entered into a distribution partnership for its Unyvero A50 system and in vitro diagnostic tests with Fisher Healthcare, a division of Thermo Fisher Scientific.

On April 14, DiaSorin announced that Mr Tony Chan is the President of DiaSorin China. He will also serve as the Chairman of the Board of Directors of DiaSorin China.

Molecular pathology firm Xyall and digital pathology firm Indica Labs said Monday that they have inked a global partnership to combine their technologies to deliver a fully digital and automated workflow for tissue macro dissection for molecular diagnostic testing.

Oxford Nanopore Technologies plc and bioMérieux SA announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.

Eastern Money Choice data shows that as of April 13, 28 listed companies in the medical device category have disclosed their 2022 annual reports, of which 18 companies have achieved year-on-year growth in net profit, accounting for 64.29%.

Agena Bioscience and nRichDX said Friday that they have entered a commercial partnership to co-promote their products to researchers developing liquid biopsy applications on Agena's MassArray platform.

Merck and Prometheus Biosciences, Inc. announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.

Alzheimer's disease (AD) is a common neurodegenerative disease that affects the cognitive and memory abilities of the brain.

Pillar Biosciences said on Thursday that it has acquired a nonexclusive license to high-throughput screening-related intellectual property from Dutch ag-bio firm KeyGene.